ARDX - ア―デリックス （Ardelyx Inc.） ア―デリックスARDXのチャート
ARDXの企業情報
| symbol | ARDx |
|---|---|
| 会社名 | Ardelyx Inc （ア―デリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アーデリックス(Ardelyx Inc.)は臨床段階のバイオ医薬品会社である。同社の治療法は心臓麻痺及び胃腸（GI）疾患の治療に重点を置く。同社はバイオ医薬品の研究、開発と商品化事業を通じて事業を運営する。同社の製品ラインには、心臓血管系ポートフォリオと胃腸ポートフォリオを含む。同社の心臓血管系ポートフォリオは慢性腎疾患（CKD）と心不全患者にある高カリウム血症の治療向け第III相臨床開発中のRDX7675及び透析末期腎疾患（ESRD）患者にある高リン酸血症治療向け第III相臨床開発中のtenapanorという2つの第III相臨床製品候補を含む。心臓血管系ポートフォリオには、tenapanor、RDX7675、RDX013及びRDX011を含む。胃腸ポートフォリオは便秘を伴う過敏性腸症候群（IBS-C）の治療のために、tenapanorによって導かれる。胃腸ポートフォリオには、tenapanor、RDX8940、RDX011及びRDX023が含まれる。 ア―デリックスは米国の臨床段階のバイオ医薬品企業。GIおよび代謝性疾患の治療ための胃腸管で排他的に動作する小分子治療薬の発見、開発、商業化に焦点を当てている。製品候補のTenapanorは、胃腸管におけるナトリウムのトランスポ―タ―の阻害剤投与小分子の経口剤。 ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada. |
| 本社所在地 | 34175 Ardenwood Boulevard Suite 200 Fremont CA 94555 USA |
| 代表者氏名 | David M. Mott デビッド・モット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-745-7047 |
| 設立年月日 | 39356 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 75人 |
| url | www.ardelyx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ardx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -47.36200 |
| 終値（lastsale） | 3.96 |
| 時価総額（marketcap） | 245732853.96 |
| 時価総額 | 時価総額（百万ドル） 248.21500 |
| 売上高 | 売上高（百万ドル） 44.35000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 84.32000 |
| 当期純利益 | 当期純利益（百万ドル） -49.92000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ardelyx Inc revenues increased from $0K to $2.4M. Net loss decreased 27% to $39.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - other decrease of 32% to $27.5M (expense) Stock-based Compensation in Research and decrease of 23% to $1.9M (expense). |
ARDXのテクニカル分析
ARDXのニュース
Jefferies initiates coverage of Ardelyx Inc at ''buy'' with a price target of $6.00 2023/05/30 07:03:36 Investing.com
https://www.investing.com/news/pro/ardelyx-inc-receives-investment-bank-analyst-rating-update-3093381
Jefferies Assumes Ardelyx, Inc at Buy 2023/05/30 07:02:01 Investing.com
https://www.investing.com/news/pro/jefferies-assumes-ardelyx-inc-at-buy-432SI-3093378
Ardelyx: Final Countdown Begins 2023/05/18 13:17:51 Seeking Alpha
Ardelyx announced that FDA accepted its resubmission of NDA for XPHOZAH for the control of serum phosphate in adult patients with chronic kidney disease. Read more here.
Ardelyx''s tenapanor NDA resubmission accepted by FDA 2023/05/17 12:03:35 Seeking Alpha
The US FDA has accepted an NDA resubmission from Ardelyx (ARDX) for Xphozah (tenapanor) as a chronic kidney disease treatment. Read more here.
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) 2023/05/17 11:30:00 GlobeNewswire
User Fee Goal Date: October 17, 2023 User Fee Goal Date: October 17, 2023
Cantor Fitzgerald maintains Ardelyx Inc at Neutral with a price target of $5.00 2023/05/04 14:11:37 Investing.com
https://www.investing.com/news/pro/ardelyx-inc-receives-investment-bank-analyst-rating-update-3073048
Ardelyx, Inc. (ARDX) Q1 2023 Earnings Call Transcript 2023/05/04 02:51:04 Seeking Alpha
Ardelyx, Inc. (NASDAQ:NASDAQ:ARDX) Q1 2023 Results Earnings Conference Call May 4, 2023 4:30 PM ETCompany ParticipantsCaitlin Lowie - Vice President, Corporate Communications and Investor…
Ardelyx GAAP EPS of -$0.13 misses by $0.03, revenue of $11.4M beats by $0.99M 2023/05/03 20:18:17 Seeking Alpha
Ardelyx press release (ARDX): Q1 GAAP EPS of -$0.13 misses by $0.03.Revenue of $11.4M (+2325.5% Y/Y) beats by $0.99M.As of March 31, 2023, the company had total cash, cash…
Recap: Ardelyx Q1 Earnings 2023/05/03 20:16:39 Benzinga
Ardelyx (NASDAQ: ARDX ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:02 PM. Here''s what investors need to know about the announcement. Earnings Ardelyx missed estimated earnings by 30.0%, reporting an EPS … Full story available on Benzinga.com
Ardelyx: Q1 Earnings Snapshot 2023/05/03 20:10:03 WTOP
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Ardelyx Inc. (ARDX) on Wednesday reported a loss of $26.8 million in…
Top Healthcare Stocks for April 2023 2023/03/30 21:22:28 Investopedia
Top healthcare stocks include Theravance Biopharma for best value, ShockWave Medical for fastest growth, and Ardelyx for most momentum.
Do you want to know where to find good stock? Take a look at Ardelyx Inc.’s (NASDAQ:ARDX) Sentiment Analysis 2023/03/28 16:16:00 US Post News
Ardelyx Inc. (ARDX)’s stock has witnessed a price declined of -1.27% from the previous close with its current price standing at $4.26. Its current price is -3.51% under its 52-week high of $4.42 and 770.05% more than its 52-week low of $0.49. Based on the past 30-day period, the stock price is -3.47% below the […]
7 Core Stocks to Build a Solid Portfolio Around 2023/03/13 10:30:14 InvestorPlace
One of the most important things about finding stocks to buy is having a diversified portfolio. You want to spread your money out in different sectors so you’re not hurt if one part of the market suddenly gets into trouble. Moderation is the key to finding the best stocks to buy, as it is in so many things. Don’t be afraid to try some aggressive plays with a small portion of your nest egg; manage your risk management accordingly. As with building any layered portfolio, your collection of holdings is only as good as its core. Have a solid core of stocks that you can rely on before you can even think about diversifying with some exotic picks. The Portfolio Grader is an outstanding tool for this exercise, as it will help you choose some highly rated core stocks to buy that based on earnings history, analyst sentiment, momentum and other factors. You’ll enjoy your investing journey more if you know every quarter that you can rely on your core to give you a solid foundation, making these some of the best stocks to buy.
Is Now An Ideal Time To Purchase Ardelyx Inc. (NASDAQ: ARDX) Stock? 2023/03/08 13:00:00 Stocks Register
Ardelyx Inc. (NASDAQ:ARDX) traded at $3.94 at close of the session on Tuesday, 03/07/23, made an upward move of 1.03% on its previous day’s price. Looking at the stock we see that its previous close was $3.90 and the beta (5Y monthly) reads 1.15 with the day’s price range being $3.915 – $4.09. In terms … Is Now An Ideal Time To Purchase Ardelyx Inc. (NASDAQ: ARDX) Stock? Read More »
Tips For Effortless money: Ardelyx, Inc. (NASDAQ:ARDX 1.03%), Desktop Metal, Inc. (NYSE:DM -4.17%) 2023/03/08 10:51:00 Stock Equity
ARDX has seen its SMA50 which is now 32.69%. In looking the SMA 200 we see that the stock has seen a 149.11%. DM has seen its SMA50 which is … The post Tips For Effortless money: Ardelyx, Inc. (NASDAQ:ARDX 1.03%), Desktop Metal, Inc. (NYSE:DM -4.17%) appeared first on Stocks Equity .